Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States.
- DOI
- 10.1007/s40261-026-01560-0
- Published
- 2026 Jul
- Container
- Clinical drug investigation
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40261-026-01560-0,
title = {Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States.},
author = {Adjei K and Diaby V and Li M and Sherbeny F and Suther S and Ali AA},
year = {2026},
journal = {Clinical drug investigation},
doi = {10.1007/s40261-026-01560-0},
url = {https://doi.org/10.1007/s40261-026-01560-0}
}RIS
TY - JOUR TI - Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States. AU - Adjei K AU - Diaby V AU - Li M AU - Sherbeny F AU - Suther S AU - Ali AA PY - 2026 JO - Clinical drug investigation DO - 10.1007/s40261-026-01560-0 UR - https://doi.org/10.1007/s40261-026-01560-0 ER -
APA
K, A., V, D., M, L., F, S., S, S., & AA, A. (2026). Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States.. Clinical drug investigation. https://doi.org/10.1007/s40261-026-01560-0
Source records
- pubmed · retrieved 2026-09-27T09:40:20.796Z